EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific cancer therapies.

On Wednesday, EpimAb Biotherapeutics Inc. announced the series B round, which was co-led by Chinese VCs SDIC and Sherpa Healthcare Partners, both new investors. New investor Southern China Venture Capital (SCVC) also participated, along with existing investors Oriza Seed Venture Capital, Decheng Capital, 3E Bioventures Capital and Trend Investment Group...